- Home
- MOBX vs ESLA Comparison
MOBX vs ESLA Comparison
Compare MOBX & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOBX | ESLA |
|---|---|---|
| Founded | 2020 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 32.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MOBX | ESLA |
|---|---|---|
| Price | $1.11 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 656.0K | 24.7K |
| Earning Date | 05-15-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,442,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 426.31 | N/A |
| 52 Week Low | $0.13 | $0.68 |
| 52 Week High | $4.25 | $3.15 |
Technical Indicators
Market Signals| Indicator | MOBX | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 30.18 | 48.74 |
| Support Level | $1.03 | $0.70 |
| Resistance Level | $1.33 | $0.85 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 14.49 | 40.62 |
Price Performance
Historical ComparisonAbout MOBX Mobix Labs Inc.
Mobix Labs Inc designs, develops and sells components and systems for wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. Its wireless systems solutions include products for RF and millimeter wave (mmWave) communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the defense, aerospace, commercial and industrial sectors. The majority of the company's revenue is derived from product sales to equipment manufacturers. Geographically, it generates the maximum revenue from the United States.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.